Drug Profile


Alternative Names: CGP 48933; Diovan; Diovane; Kalpress; Miten; Nisis; Provas; Tareg; Valpression; Vals; Varexan

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer ESTEVE; JW Pharmaceutical; Novartis; Zeneca Farma
  • Class Antihypertensives; Branched-chain amino acids; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Essential hypertension; Heart failure; Hypertension; Postmyocardial infarction
  • Discontinued Pulmonary fibrosis; Type 2 diabetes mellitus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Hypertension(In volunteers) in India (PO, Liquid)
  • 21 Aug 2017 Novartis initiates a phase I trial in Hypertension (In volunteers) in India (PO, Liquid) (EudraCT2016-004323-23)
  • 24 Jan 2017 Novartis completes a phase III trial in Hypertension (In children) in Belgium, Brazil, France, Germany, Guatemala, Hungary, Italy, Lithuania, Poland and Spain (NCT01617681) (EudraCT2011-005991-40)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top